Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers — Stella

Home/Healthy Volunteer/Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

View on ClinicalTrials.gov

Recruiting

Back to Healthy Volunteer trials

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Early testing

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment target

~300 participants

Started

April 2019

Primary completion

October 2026

Age range

18 Years – 65 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.